[Use of XXXX for @entity548 control in myocardial revascularization].

@entity1 @entity410 @entity1087 @entity548 @entity1764 @entity177 @entity927 @entity583
PURPOSE: To compare two groups of 80 @entity1 undergoing to myocardial revascularization with the use of antifibrinolytic drug @entity927 and its efficacy in reduce @entity548 and blood transfusion. METHODS: Prospective analysis of two groups of 80 @entity1 . Group A-no antifibrinolytic therapy (dec 91-may 92) and group B-fibrinolytic therapy- @entity927 -10g EV (jun-dec/92). Quantification of mediastinal drainage over 12h as well as the blood or derivatives received at the same time. RESULTS: Hospital mortality: group A-3.8%, group B-2.5%. Drainage (12h): group A-602 +/- 547 ml and group B-260 +/- 260 ml (p < 0.001). Blood transfusion (12h): group A-1,782 +/- 1,163 ml and group B-1,105 +/- 839 ml (p < 0.001). COMPLICATIONS: group A-two cases of intraoperative @entity583 , one episode of @entity1087 ; group B-one case of intraoperative MI, one reoperation for @entity548 control, one episode of @entity1087 , one of @entity177 , two @entity1764 and one @entity410 . The mean hospitalization time was ten days in both groups. CONCLUSION: @entity927 was an effective drug in @entity548 control and in reducing blood transfusion in the postoperative of @entity1 submitted to myocardial revascularization.
